Skip to content
Screener

Glaukos GKOS Total Cost of Revenue

Total Cost of Revenue at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$8.05B+5.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$100.7M+69.6%
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
$2.01M-32.3%
AbbVie logo
AbbVieABBV
$4.29B-1.3%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.33M+5.3%
HRO
HarrowHROW
$17.16M+10.5%

Segments

By segment

See full
Development And Commercialization Of Ophthalmic Therapies$34.02M+26.5%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.08B+98.7%
Enterprise value$10.07B+98.2%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Net sales$185,610$124,120$336,181$230,784
Cost of sales34,01626,89667,35551,212
Gross profit151,59497,224268,826179,572
Operating expenses:
Selling, general and administrative116,06083,375209,003154,048
Research and development51,30136,53895,44668,891
Acquired in-process research and development1,500-1,500-
Total operating expenses168,861119,913305,949222,939

Item 1. Financial Statements

FAQ

What is Glaukos's total cost of revenue?
Glaukos (GKOS) reported total cost of revenue of $34.02M in Q2 2026.
How has Glaukos's total cost of revenue changed year-over-year?
Glaukos's total cost of revenue increased by 26.5% year-over-year, from $26.9M to $34.02M.
What is the long-term trend for Glaukos's total cost of revenue?
Over 4 years (2021 to 2025), Glaukos's total cost of revenue has grown at a 13.8% compound annual growth rate (CAGR), from $66.63M to $111.81M.
What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.

Ask your AI about Glaukos's total cost of revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude